

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MEHRABAN ET AL.	Examiner:	G. NICKOL
Serial No.:	09/703,350	Group Art Unit:	1642
Filed:	OCTOBER 31, 2000	Docket No.:	11669.213USU1
Confirmation No.:	3065	Customer No.:	23552
Title:	DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING THE SAME		

---

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Please charge Deposit Account No. 13-2725 for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: July 25, 2006

Katherine M. Kowalchuk  
Katherine M. Kowalchuk  
Reg. No. 36,848

**23552**

PATENT TRADEMARK OFFICE

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 11669 213USU1	Application Number: 09/703,350
	Applicant: MEHRABAN ET AL.	
	Filing Date: 10/31/2000	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Colcher et al., "Pharmacokinetics and biodistribution of genetically-engineered antibodies", <u>Q. J. Nucl. Med.</u> , 42:225-241 (1998)
		Eccles, "Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?", <u>Breast Cancer Research</u> , 3:86-90 (2001)
		Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders", <u>Cancer Research</u> , 57:4593-4599 (1997)
		"FDA Approves Avastin, A Targeted Therapy for First-Line Metastatic Colorectal Cancer Patients", Genentech: Press Releases – News Release, dated February 26, 2004

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPE 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	